Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Bailliere'S Clinical Haematology|December 1, 1995
Immunophenotype and DNA cell content in multiple myelomaJ F San Miguel, R Garcia-Sanz, M Gonzalez, et al.
Leukemia Research|June 1, 1995
In vitro autonomous proliferation in ANLL: clinical and biological significanceJ Almeida, C del Cañizo, A Orfao, et al.
Leukemia|March 13, 2001
Immunoglobulin lambda isotype gene rearrangements in B cell malignanciesT Tümkaya, M van der Burg, R Garcia Sanz, et al.
Annals of Hematology|March 17, 2010
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myelomaA Palumbo, F Davies, M Kropff, et al.
Thrombosis Research|September 29, 2006
Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphismJ R Gonzalez-Porras, F Martin-Herrero, R Garcia-Sanz, et al.
Annals of Hematology|January 5, 2002
Association of CD4+/CD56+/CD57+/CD8+(dim) large granular lymphocytic leukemia, splenic B-cell lymphoma with circulating villous lymphocytes, and idiopathic erythrocytosisM Lima, C Gonçalves, L Marques, et al.
Leukemia|May 24, 2003
Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalitiesD Primo, M D Tabernero, A Rasillo, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathiesM V Mateos, R Garcia-Sanz, R López-Pérez, et al.
Leukemia|September 3, 2010
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working GroupE Terpos, M A Dimopoulos, O Sezer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2019
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)R Garcia-Sanz, A Sureda, F de la Cruz, et al.
Pageof 2